heptapeptide is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-02-27. Numbers and descriptions here follow the published literature rather than marketing material.
Laboratory work relies on standard behavioral paradigms. Rodents are tested in the elevated plus maze, open field, and passive avoidance tasks, with outcomes compared against diazepam or vehicle controls. Intranasal dosing is used most often because it bypasses first-pass metabolism, though intraperitoneal and intravenous routes also appear in published protocols. Biochemical endpoints include tissue BDNF concentrations, cytokine levels, and monoamine metabolites. Human data are limited to small Russian trials reporting reduced anxiety scores; most were not prospectively registered, and few employed independent outcome assessment.
Measuring peptide exposure inside the brain is technically difficult. Selank is degraded rapidly in plasma, and assays must separate intact peptide from fragments, which favors targeted mass spectrometry over immunoassays alone. Reported half-lives are short, on the order of minutes, so effects observed hours later are attributed to downstream signaling rather than to the parent compound. Blood-brain barrier permeability is debated and rarely quantified directly. Gaps include absent dose-response characterization, inconsistent reporting of purity, and almost no pharmacokinetic data from human participants.
Outside its country of origin the compound is generally handled as a research chemical rather than an approved medicine. No regulatory approval from the United States Food and Drug Administration or the European Medicines Agency has been granted for human use. Identity and purity are normally checked by reverse-phase high-performance liquid chromatography, with mass spectrometry used to confirm the molecular mass. Lyophilised material is stored cold and desiccated, and repeated freeze-thaw cycles are avoided.
Published work on this peptide almost always uses intranasal delivery, with drops or a spray applied to the nasal mucosa. Some animal experiments have used subcutaneous or intraperitoneal injection, and a smaller number have compared routes directly. Oral administration is not a focus of the literature, because short peptides of this size are broken down by digestive enzymes and cross intestinal barriers poorly. How much of an intranasal dose reaches the bloodstream intact in humans remains an open question.
Animal studies have examined behaviour in tests of anxiety, memory retention and stress response, and several report changes in neurotrophic or neurotransmitter-related markers. The human evidence base is much smaller, consisting mainly of short trials conducted in Russia with limited reporting in English-language journals. Sample sizes are modest and outcome measures vary between studies, so the findings are best described as preliminary. Independent replication under modern trial standards has not been widely reported.
| Property | Value | Notes |
|---|---|---|
| Principal proposed target | GABA-A receptor complex | Hypothesis derived mainly from animal pharmacology |
| Common behavioral assay | Elevated plus maze | Rodent test for anxiety-like behavior |
| Reported molecular marker | Hippocampal BDNF expression | Measured by immunoassay or mRNA quantification |
| Typical dosing route | Intranasal | Chosen to reduce first-pass metabolism |
| Reported plasma half-life | Minutes | Based on limited peptide stability data |
Enzymatic stability motivates the extra three residues at the carboxyl end. Native tuftsin is cleaved quickly by circulating aminopeptidases and carboxypeptidases, which limits its duration of action and its usefulness as a tool compound. Extending the chain with proline-rich segments is a common design tactic because proline constrains the backbone and slows proteolysis. The same Pro-Gly-Pro motif appears in other Russian-developed peptides of the era. Whether the full seven-residue chain is required for activity, or whether it acts mainly as a prodrug releasing tuftsin, remains unresolved.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. Its four N-terminal residues reproduce tuftsin, a tetrapeptide fragment of the immunoglobulin heavy chain, while the C-terminal Pro-Gly-Pro extension is a synthetic addition. The peptide has a molecular mass near 752 daltons and carries a net positive charge at physiological pH because of the arginine and lysine side chains. Published indexes list it under the name Selank and the sequence abbreviation TKPRPGP. Solid-phase peptide synthesis is the standard production route for research quantities.
The compound has a calculated molecular weight near 751.9 daltons and carries a net positive charge at physiological pH because of its arginine residue. It dissolves freely in water and in common aqueous buffers, and typically appears as a white or off-white lyophilized powder. The amide backbone makes the molecule susceptible to peptidases, which limits oral use and favors intranasal or parenteral routes. Nomenclature in the literature varies: the substance is also described by the sequence abbreviation TP-7 and by a Russian trade designation.
Regulatory status differs sharply by region. Selank holds a Russian marketing authorization, where it is supplied mainly as nasal drops, while authorities elsewhere have not approved it for medical use. Material sold internationally is therefore usually labeled as a research chemical rather than a medicine. Peer-reviewed publications come predominantly from Russian laboratories, and sample sizes are generally small. Whether the compound produces comparable effects under independent, well-controlled replication remains an open question that the broader literature has not settled.
Selank is a synthetic heptapeptide developed in Russia as a structural analogue of tuftsin, a naturally occurring immunomodulatory tetrapeptide. Its sequence, Thr-Lys-Pro-Arg-Pro-Gly-Pro, keeps the tuftsin core at the N-terminus and appends a Pro-Gly-Pro tail. Researchers at the Institute of Molecular Genetics in Moscow synthesized the compound during the 1990s while searching for peptides with combined anxiolytic and immunomodulatory activity. The added tail was intended to resist enzymatic cleavage and prolong the molecule's presence in circulation.
==== Backup site ==== A backup site or disaster recovery center is used to store data that can enable computer systems and networks to be restored and properly configured in the event of a disaster. Some organisations have their own data recovery centres, while others contract this out to a third-party. Due to high costs, backing up is rarely considered the preferred method of moving data to a DR site. A more typical way would be remote disk mirroring, which keeps the DR data as up to date as possible.
=== Synthesis === Adrenochrome is readily synthesized from commercially available reagents: chloroacetic acid and catechol react in the presence of phosphoryl chloride to yield chloroacetylcatechol. After purification, chloroacetylcatechol is reacted with aqueous methylamine and treated with hydrochloric acid, yielding adrenalone hydrochloride. This is then hydrogenated to racemic adrenaline. Finally, adrenaline is oxidized to adrenochrome by an appropriate oxidizing agent such as silver oxide.
president Donald Trump, FIFA suspended the ban. The Royal Belgian Football Association, Belgium manager Rudi Garcia, and UEFA were critical of the decision. Following the full-time whistle in the final, Argentina player Leandro Paredes was involved in altercations with Spain players Eric García and Gavi. While FIFA initially reported a red card for these incidents, the organization later confirmed that Paredes was not punished at the time. The following suspensions were accumulated during the tournament:
Fluoroalanine, specifically 3-fluoro-alanine, is a fluorinated analogue of the amino acid alanine. Historically considered as an antibiotic, it also has potential applications as a radioactive tracer in positron emission tomography (PET).
==== United States ==== The US Food and Drug Administration (FDA) considers safe beverages containing less than 0.02% caffeine; but caffeine powder, which is sold as a dietary supplement, is unregulated. It is a regulatory requirement that the label of most prepackaged foods must declare a list of ingredients, including food additives such as caffeine, in descending order of proportion. However, there is no regulatory provision for mandatory quantitative labeling of caffeine, (e.g., milligrams caffeine per stated serving size). There are a number of food ingredients that naturally contain caffeine. These ingredients must appear in food ingredient lists. However, as is the case for "food additive caffeine", there is no requirement to identify the quantitative amount of caffeine in composite foods containing ingredients that are natural sources of caffeine. While coffee or chocolate are broadly recognized as caffeine sources, some ingredients (e.g., guarana, yerba maté) are likely less recognized as caffeine sources. For these natural sources of caffeine, there is no regulatory provision requiring that a food label identify the presence of caffeine nor state the amount of caffeine present in the food. The FDA guidance was updated in 2018.
Sources: en.wikipedia.org
Post-SSRI sexual dysfunction (PSSD) is an iatrogenic condition in which sexual side effects persist after discontinuation of serotonin reuptake inhibiting antidepressants, including venlafaxine. Characteristic symptoms include genital numbness, pleasureless or weak orgasm, loss of libido, and erectile dysfunction; non-sexual symptoms such as emotional blunting and cognitive impairment may also occur. The condition can arise after even brief exposure to a serotonin reuptake inhibitor and may persist indefinitely; there is currently no established treatment. A case study published in 2023 specifically documented PSSD symptoms—including low libido, delayed ejaculation, and erectile dysfunction—developing after discontinuation of venlafaxine, with 5-HT1A receptor downregulation proposed as a possible mechanism. A 2023 retrospective cohort study of over 12,000 males estimated the risk of irreversible sexual dysfunction (as measured by persistent need for phosphodiesterase inhibitors after antidepressant cessation) at approximately 0.46% of patients treated with serotonergic antidepressants, including SNRIs. The DSM-5 noted in 2013 that serotonin reuptake inhibitor–induced sexual dysfunction may persist after the agent is discontinued. In 2019, the European Medicines Agency's Pharmacovigilance Risk Assessment Committee recommended that product labels for all SSRIs and SNRIs, including venlafaxine, be updated to warn that sexual dysfunction may be long-lasting after treatment is stopped.
The New York Times had also released a video documentary "When A President Says I'll Kill You", which depicts Duterte's war on drugs through a local photographer's eyes. On August 17, 2017, HRW called Duterte a threat to the human rights community after he made threats against human rights activists.
The cover version by Selena Gomez was released on 22 July 2009 as part of the Radio Disney iTunes Pass, serving as a promotional single for the soundtrack of the Disney Channel television series Wizards of Waverly Place. It debuted and peaked at no. 61 on the U.S. Billboard Hot 100 chart with 42,000 downloads. It also peaked at No. 80 on the Canadian Hot 100 chart, No. 5 on the Norwegian Singles Chart and at No. 90 on the UK Singles Chart. It has sold 563,000 copies in the United States. The song was featured in the television film Wizards of Waverly Place: The Movie. The music video premiered on the Disney Channel on 24 July 2009, and was directed by Roman Perez.
== History == In 1968, a reduced T4 half-life in athletes was discovered. This was the first awareness of thyroid hormone concentration alterations that were not a result of thyroid gland or pituitary dysfunction. In 1971, they also found a transient increase in T4 during bicycle training. In 1973, Rothenbuchner et al. discovered that starvation is correlated with reduced T3 concentration. Following this, a similar phenotype was noted in patients with critical illness, tumors, and uremia. The alternative phenotype of type-2 thyroid allostasis was first predicted in 1968, when John W. Mason expected the concentrations of thyroid hormones to rise in situations of psychosocial stress. Mason's postulate was later confirmed by numerous studies.
=== Milling === During the drug manufacturing process, milling is often required in order to reduce the average particle size in a drug powder. There are a number of reasons for this, including increasing homogeneity and dosage uniformity, increasing bioavailability, and increasing the solubility of the drug compound. In some cases, repeated powder blending followed by milling is conducted to improve the manufacturability of the blends.
Sources: en.wikipedia.org
== Society == Mass Party, a political party in Thailand (2006–2009?) Mass society, a society based on relations between huge numbers of people, whose prototypical denizen is the "mass man" Mass politics, politics in the mass society, featuring especially the modern political party
==== Philippines ==== Think tanks in the Philippines could be generally categorized in terms of their linkages with the national government. Several were set up by the Philippine government for the specific purpose of providing research input into the policy-making process.
== External links == Overview of Colombian–FARC Peace Process Who are the victims? – The aftermath of violence in Colombia – (Former combatants in Colombia's internal armed conflict spent two years painting their experiences. They face difficult decisions about what to remember, what to forget and how to forgive) "Colombia Page on InSight Crime". Archived from the original on July 26, 2011. Retrieved March 29, 2011. (Ongoing reporting on the Colombian conflict and active criminal groups) "Evolution of the Colombian Civil War". Paul Wolf. Archived from the original on February 3, 2006. Retrieved February 24, 2006. (collection of declassified U.S. documents online) Michael Evans, ed. (May 3, 2002). "War in Colombia: Guerrillas, Drugs and Human Rights in U.S.-Colombia Policy, 1988–2002". National Security Archive Electronic Briefing Book No. 69. National Security Archive. "America's Other War: Terrorizing Colombia". Retrieved February 25, 2006.{{cite web}}: CS1 maint: deprecated archival service (link) Plan Colombia by Carmen Guhn-Knight "Rule of Law in Armed Conflict: Colombia". RULAC Project. Archived from the original on July 6, 2011. Retrieved March 23, 2009. "Q&A: Colombia's civil conflict". BBC News. December 23, 2009. Retrieved February 24, 2006. "Colombia Program". Center for International Policy. Retrieved February 24, 2006. "Accord issue on Colombia's peace process". Alternatives to war. Archived from the original on November 17, 2006. Retrieved November 18, 2006. (In Spanish and English with chronology and key texts and agreements) "CERAC".
Population coverage: some countries have large surveillance networks that cover most of their population, while others use a smaller subset of hospitals and laboratories to generate data intended to be representative of the broader population. Sampling: EARS-Net data are only collected for invasive isolates (from blood or cerebrospinal fluid). These samples may not be representative of the members of this species that can colonize and infect humans, so resistance rates for other infections, such as urinary tract infections may vary. In some settings, laboratory microbiology work may only be performed in cases where initial antibiotic treatment has failed, leading to an overestimation of resistance rates. Laboratory routines and capacity: interpretation of minimum inhibitory concentration may vary across laboratories and countries, depending on current practice. Recommendations around converting minimum inhibitory concentration to resistance status also change over time, making comparison of resistance rates over time challenging.
Sources: en.wikipedia.org
Intranasal administration predominates in both animal and human research because it avoids hepatic first-pass metabolism. Injectable and intraperitoneal routes appear in animal work mainly for comparison.
Behavioral endpoints include time spent in open arms of the elevated plus maze and avoidance latencies. Biochemical endpoints include BDNF concentration, cytokine levels, and monoamine metabolite ratios in brain tissue.
Most published studies are small, originate from a limited number of laboratories, and lack independent replication. Dose-response relationships, measured brain exposure, and long-term outcomes are not well characterized.
Most published work uses intranasal application, either as drops or as a nasal spray. Injection routes appear in a smaller set of animal experiments. Oral use is uncommon in the literature because peptide breakdown and poor absorption limit this route.